Anteo Diagnostics (ASX: ADO) is a global medical technology company, developing and commercialising products for sale into the lifesciences, in-vitro diagnostics, point of care, medical devices and bioseparations markets.
The Anteo group owns a patented nanoglue technology, which is used by healthcare customers as an addition to their existing tests, to consistently enable laboratory test results that can either be delivered faster, cheaper or with greater specificity.
MIX&GO™ HEALTHCARE NANOGLUEAttaching fragile proteins to synthetic surfaces is often required in modern drug discovery research, life science research and development, as well as for the development of therapeutic and diagnostic products. Depending on the particular method and application, many different synthetic materials – magnetic beads, various plastics, glass, metals, and porous membranes – are used.
The surface characteristics of these materials vary enormously as do the type, size, and number of biomolecules to be immobilised. Maintaining the activity of biomolecules on these synthetic surfaces continues to be an industry challenge. Standard chemistries tend to damage a large percentage of the biomolecules attached to the synthetic surface.
Damage results in reduction or loss of function of the biomolecule requiring the manufacturer to either use a large excess of these expensive molecules or sacrifice performance in their tests.
Mix&Go improves diagnostic tests, and is a cheaper and easier alternative to traditional chemistries such as EDC and NHS. Using a surface coating such as Mix&Go Activation Reagent that relies on coordination chemistry for multipoint binding, antibodies will take advantage of the gentle yet secure binding nature of the reagent, and will retain higher functionality and stability than EDC or NHS Chemistry.
Scientists can also reduce reagent preparation time by 3-4 hours by using Mix&Go instead of EDC or NHS chemistry. In addition, Mix&Go is water based and reduces the amount of hazardous chemicals scientists work with.
Outside of the medical technology and life sciences space, an opportunity exists that has the potential to deliver innovations to the $30 billion lithium ion batteries market, a market which is expected to be worth $50 billion per annum by 2018.
Early, promising data below (figure 1) compares existing battery material on the market today to battery material with our nanoglue technology added:
What does this mean? Anteo nanoglue can:
Image credit: Anteodx.com